Ignacio Porras

Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial

Emilio Alba, Joan Albanell, Juan de la Haba-Rodríguez et al. · British Journal of Cancer · 2014 · 83 citations · Full text

Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC)

Jaume Capdevila, José Trigo, Javier Aller et al. · European Journal of Endocrinology · 2017 · 37 citations · Full text

SEOM clinical guideline thyroid cancer (2019)

Enrique Gallardo, Jesús E. Medina, Juan Cristóbal Sánchez et al. · Clinical & Translational Oncology · 2020 · 36 citations · Full text

Circulating Tumor Cells as a Biomarker of Survival and Response to Radium-223 Therapy: Experience in a Cohort of Patients With Metastatic Castration-Resistant Prostate Cancer

Joan Carles, Daniel Castellano, María-José Méndez-Vidal et al. · Clinical Genitourinary Cancer · 2018 · 32 citations

Urology, Genitourinary Cancer, Medicine +6

Biweekly gemcitabine, doxorubicin, and paclitaxel as first-line treatment in metastatic breast cancer. Final results from a phase II trial.

Pedro Sánchez‐Rovira, A. Jaén, Ignacio Porras et al. · PubMed · 2001 · 24 citations

Biweekly Gemcitabine, Metastatic Breast Cancer, Oncology +11